ABIVAX Société Anonyme (NASDAQ:ABVX) Given Average Rating of “Moderate Buy” by Analysts

Shares of ABIVAX Société Anonyme (NASDAQ:ABVX) have been given an average rating of “Moderate Buy” by the seven brokerages that are covering the company, Marketbeat.com reports. One analyst has rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $36.50.

Separately, Laidlaw began coverage on ABIVAX Société Anonyme in a report on Monday, July 29th. They set a “buy” rating and a $48.00 price objective for the company.

ABIVAX Société Anonyme Price Performance

Shares of ABIVAX Société Anonyme stock opened at $10.13 on Thursday. The business has a 50 day moving average price of $11.18 and a 200-day moving average price of $12.85. ABIVAX Société Anonyme has a 52 week low of $7.99 and a 52 week high of $17.02.

Hedge Funds Weigh In On ABIVAX Société Anonyme

Several large investors have recently made changes to their positions in ABVX. Janus Henderson Group PLC grew its position in ABIVAX Société Anonyme by 18.2% in the 1st quarter. Janus Henderson Group PLC now owns 851,839 shares of the company’s stock worth $12,113,000 after purchasing an additional 131,414 shares during the period. Kennedy Capital Management LLC boosted its holdings in ABIVAX Société Anonyme by 35.3% in the 1st quarter. Kennedy Capital Management LLC now owns 120,168 shares of the company’s stock worth $1,718,000 after buying an additional 31,331 shares during the period. BNP Paribas Financial Markets bought a new position in ABIVAX Société Anonyme in the 1st quarter worth $81,000. Finally, Capstone Investment Advisors LLC lifted its stake in ABIVAX Société Anonyme by 9.0% in the 1st quarter. Capstone Investment Advisors LLC now owns 62,966 shares of the company’s stock worth $900,000 after purchasing an additional 5,199 shares in the last quarter. 47.91% of the stock is currently owned by hedge funds and other institutional investors.

ABIVAX Société Anonyme Company Profile

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.